{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:04:41Z","timestamp":1784178281521,"version":"3.55.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003996","name":"Kunming Medical University","doi-asserted-by":"publisher","award":["QL-JBGS-14, 2025S270"],"award-info":[{"award-number":["QL-JBGS-14, 2025S270"]}],"id":[{"id":"10.13039\/501100003996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202401AY070001-147 , 202503AP140033"],"award-info":[{"award-number":["202401AY070001-147 , 202503AP140033"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) inevitably develop resistance to EGFR-tyrosine kinase inhibitors (TKIs). Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic strategy in this setting; however, no meta-analysis has systematically evaluated ADC efficacy and safety specifically in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for clinical trials evaluating ADCs in patients with EGFR-mutant NSCLC after TKI failure, published up to December 2025. The primary endpoint was objective response rate (ORR). Secondary endpoints included median progression-free survival (mPFS), median overall survival (mOS), and hazard ratios (HR) for PFS and OS in randomized controlled trials (RCTs). Pooled proportions were estimated using the Freeman-Tukey double arcsine transformation with a DerSimonian-Laird random-effects model, and subgroup analyses were stratified by ADC target antigen. A random-effects meta-regression was used to assess whether the median number of prior treatment lines explained heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine studies encompassing 1,092 patients were included. The pooled ORR was 44.7% (95% CI 36.7%\u201352.9%; I\u00b2 = 84.4%), with substantial heterogeneity driven by between-target differences. Subgroup analysis demonstrated a significantly higher ORR for TROP2-targeting ADCs (50.6%; 95% CI 40.3%\u201360.9%) than for HER3-targeting ADCs (34.2%; 95% CI 28.8%\u201339.8%) (P for interaction = 0.006). Among three RCTs, the two trials of sacituzumab tirumotecan (Sac-TMT) versus chemotherapy yielded a pooled HR of 0.40 (95% CI 0.25\u20130.64) for PFS and 0.57 (95% CI 0.44\u20130.76; I\u00b2 = 0%) for OS, both favouring ADC therapy; by contrast, the phase III HERTHENA-Lung02 trial of patritumab deruxtecan (HER3-DXd) improved PFS (HR 0.77; 95% CI 0.63\u20130.94; P\u00a0=\u00a00.011), but OS data were immature at the time of the analysis. Across studies, mPFS ranged from 5.5 to 11.1 months, and mature mOS data were available from only three studies (range 11.9\u201316.2 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ADCs demonstrate substantial antitumour activity in EGFR-mutant NSCLC after TKI resistance, but efficacy appears target- and drug-specific rather than a uniform class effect. Among the agents studied, only the TROP2-ADC sacituzumab tirumotecan has shown improvement in both PFS and OS over chemotherapy, whereas the HER3-ADC patritumab deruxtecan improved PFS without an OS benefit. Given high between-study heterogeneity and OS immaturity in most studies, these findings support ADCs\u2014particularly TROP2-directed agents\u2014as a key therapeutic option for this difficult-to-treat population, while underscoring the need for biomarker-guided patient selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1832920","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:21:23Z","timestamp":1784175683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiao","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery II, The Third Affiliated Hospital of Kunming Medical University\/Yunnan Cancer Hospital\/Peking University Cancer Hospital Yunnan Branch","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery II, The Third Affiliated Hospital of Kunming Medical University\/Yunnan Cancer Hospital\/Peking University Cancer Hospital Yunnan Branch","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery II, The Third Affiliated Hospital of Kunming Medical University\/Yunnan Cancer Hospital\/Peking University Cancer Hospital Yunnan Branch","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistic","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3322\/caac.21877","article-title":"Personalized care for patients with EGFR-mutant non-small cell lung cancer: navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120858","article-title":"Personalized therapy for lung cancer: striking a moving target","volume":"3","author":"Pakkala","year":"2018","journal-title":"JCI Insight"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41698-021-00232-w","article-title":"Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC","volume":"5","author":"Peters","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S154110","article-title":"Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review","volume":"11","author":"Han","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02614-x","article-title":"Real-world data about treatment outcomes for patients with EGFR-mutated NSCLC resistance to osimertinib and platinum-based chemotherapy","volume":"40","author":"Hayashi","year":"2023","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduc Tgt Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1252652","article-title":"A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer","volume":"13","author":"Hsu","year":"2023","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.108066","article-title":"Antibody-drug conjugates: a new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer","volume":"223","author":"Deng","year":"2026","journal-title":"Pharmacol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant NSCLC","volume":"394","author":"Fang","year":"2025","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00124-7","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12885-025-15461-6","article-title":"Evaluating the efficacy and safety of antibody-drug conjugates in non-small cell lung cancer: a systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2026","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-376","article-title":"Efficacy and safety of antibody-drug conjugates in the treatment of non-small cell lung cancer: a systematic review and meta-analysis of prospective clinical trials","volume":"14","author":"Jin","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3892\/ol.2025.14727","article-title":"Antibody drug conjugates demonstrate potential as HER-2-targeted therapies for NSCLC","volume":"30","author":"Zhao","year":"2025","journal-title":"Oncol Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70178","article-title":"Treatment-related adverse events of antibody-drug conjugate monotherapy in non-small cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Thorac Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111750","article-title":"Efficacy and safety of TROP-2-targeting antibody-drug conjugate treatment in previously treated patients with advanced non-small cell lung cancer: a systematic review and pooled analysis of reconstructed patient data","volume":"17","author":"Stumpo","year":"2025","journal-title":"Cancers"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B31","volume-title":"The Newcastle-Ottawa Scale (Nos) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2014"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Ctrl Clin Trials"},{"key":"B34","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5","author":"Higgins","year":"2024"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.01.010","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Fang","year":"2025","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small cell lung cancer after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S492200","article-title":"Current status and future prospects of TROP-2 ADCs in lung cancer treatment","volume":"18","author":"Li","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies","volume":"170","author":"Johnson","year":"2022","journal-title":"Lung Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04093-z","article-title":"Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments","volume":"148","author":"Omori","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18007","article-title":"Prognostic significance of HER3 in patients with Malignant solid tumors","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1238","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT008","article-title":"First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors","volume":"85","author":"Lu","year":"2025","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-5736","article-title":"AZD9592: an EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond","volume":"83","author":"Comer","year":"2023","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359251387393","article-title":"Antibody-drug conjugates versus chemotherapy in previously treated non-small-cell lung cancer: a systematic review and meta-analysis","volume":"17","author":"Khan","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832920\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:21:26Z","timestamp":1784175686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832920\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":52,"alternative-id":["10.3389\/fonc.2026.1832920"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1832920","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1832920"}}